Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir

Table 3 Adjusted clinical event rates for one-time events, by year after kidney transplantation

Proportion of patients with events	Year 1 of follow-up with leukopenia/neutropenia, n = 119971 (A)		Year 1 of follow-up without leukopenia/neutropenia, n = 34011 (B)		Relative risk A/B	Year 2-5 of follow-up with leukopenia/neutropenia2 (A)		Year 2-5 of follow-up without leukopenia/neutropenia2 (B)		Relative risk A/B
	Event rate (%)	SE (%)	Event rate (%)	SE (%)		Event rate (%)	SE (%)	Event rate (%)	SE (%)
Acute graft rejection	21.14	0.27	13.23	0.63	1.6	13.26	0.27	10.3	0.63	1.29
Graft loss	11.56	0.28	7.86	1.15	1.47	11.48	0.28	6.96	1.15	1.65
All-cause mortality	0.06	3.21	0.02	17.69	2.55	9.04	3.21	9.46	17.69	0.96

¹One-time events were evaluated over the entire duration of follow-up. Hence, the cohort of neutropenia or leukopenia was also defined using the lab data through the entire duration of follow-up. The n represented the number of patients at risk at day 0.

²The number of patients at risk after year 1 of follow-up among those with leukopenia/neutropenia by clinical event was: n = 9651 (acute graft rejection), n = 10685 (graft loss), and n = 11990 (all-cause mortality). The number of patients at risk after year 1 of follow-up among those without leukopenia/neutropenia by clinical event was: n = 2977 (acute graft rejection), n = 3141 (graft loss), and n = 3401 (all-cause mortality).